Alex Michael Azar Jr. (//; born June 17, 1967) is an American politician, attorney, former pharmaceutical lobbyist, pharmaceutical executive, and current Presidential cabinet member who serves as the United States Secretary of Health and Human Services. Azar was nominated to his post by President Donald Trump on November 13, 2017, and confirmed by the United States Senate on January 24, 2018. He was also Chairman of the White House Coronavirus Task Force from its inception in January 2020 to February 2020, when he was replaced by Vice President Mike Pence.
|24th United States Secretary of Health and Human Services|
|Assumed office |
January 29, 2018
|Preceded by||Tom Price|
|Chairman of the White House Coronavirus Task Force|
January 29, 2020 – February 26, 2020
|Preceded by||Office established|
|Succeeded by||Mike Pence|
|United States Deputy Secretary of Health and Human Services|
January 22, 2005 – February 4, 2007
|President||George W. Bush|
|Preceded by||Claude Allen|
|Succeeded by||Tevi Troy|
|General Counsel of the United States Department of Health and Human Services|
August 8, 2001 – January 22, 2005
|President||George W. Bush|
|Preceded by||Harriet S. Rabb|
|Succeeded by||Daniel Meron|
Alex Michael Azar II
June 17, 1967
Johnstown, Pennsylvania, U.S.
|Education||Dartmouth College (BA)|
Yale University (JD)
|Net worth||$8.7 million|
Azar served as General Counsel of the United States Department of Health and Human Services (HHS) from 2001 to 2005. On July 22, 2005, he was confirmed as the Deputy Secretary of Health and Human Services; he served in that capacity until his January 2007 resignation.
From 2012 to 2017, Azar was President of the U.S. division of Eli Lilly and Company, a major drug company, and a member of the board of directors of the Biotechnology Innovation Organization, a large pharmaceutical trade association.
Azar was born on June 17, 1967, in Johnstown, Pennsylvania, the son of Lynda (Zarisky) and Alex Michael Azar Sr. His father is a retired ophthalmologist who practiced ophthalmology in Salisbury, Maryland, for more than 30 years, and taught at Johns Hopkins Hospital. His grandfather emigrated from Lebanon in the early 20th century. The family originates from Amioun.
Azar attended Parkside High School in Salisbury, Maryland, where he graduated in 1985. He received a B.A. degree summa cum laude in government and economics from Dartmouth College in 1988. He belonged to the Kappa Kappa Kappa fraternity. He earned a J.D. degree from Yale Law School in 1991, where he served as a member of the executive committee of the Yale Law Journal.
After law school, from 1991 to 1992, Azar served as a law clerk for controversial Judge Alex Kozinski of the United States Court of Appeals for the Ninth Circuit. Azar left after six weeks, and was replaced in Kozinski's chambers by Brett Kavanaugh. Azar subsequently clerked for the remainder of the term for Judge J. Michael Luttig of the United States Court of Appeals for the Fourth Circuit. From 1992 to 1993, he served as a law clerk for Associate Justice Antonin Scalia of the United States Supreme Court.
From 1994 to 1996, he served as an Associate Independent Counsel for Ken Starr in the United States Office of the Independent Counsel, where he worked on the first two years of the investigation into the Whitewater controversy. At the time of Azar's appointment, he was working as an associate in Starr's law firm.
Health and Human ServicesEdit
On August 3, 2001, Azar was confirmed as General Counsel of the United States Department of Health and Human Services. George W. Bush's first HHS Secretary, Tommy Thompson, said Azar played an important role in responding to the 2001 anthrax attacks, ensuring there was a vaccine ready for smallpox, and dealing with outbreaks of SARS and influenza. On July 22, 2005, Azar was confirmed as the Deputy Secretary of Health and Human Services. He was twice confirmed unanimously by the United States Senate.
Working under Secretary Mike Leavitt, Deputy Azar supervised the operation of HHS, which would grow to an annual budget of over $1 trillion by 2017 when he was appointed Secretary. Azar led the development and approval of HHS regulations, led U.S. government efforts to encourage worldwide pharmaceutical and medical device innovation, and was in charge of the HHS response to an initiative implemented by President George W. Bush to improve government performance. Azar resigned in January 2007.
Eli Lilly & Co.Edit
In June 2007, Azar was hired by Eli Lilly and Company chief executive officer Sidney Taurel to be the company's top lobbyist and spokesman as its Senior Vice President of Corporate Affairs and Communications. Azar left the position after the 2008 United States presidential election was won by Democratic Party candidate Barack Obama and the corporation wanted to replace Azar with a Democrat in that role.
In April 2009, Azar became Vice President of Lilly's U.S. Managed Healthcare Services organization and its Puerto Rico affiliate. In 2009, the company paid $1.415 billion to settle criminal charges regarding its promotion of antipsychotic drug Zyprexa (olanzapine) for off-label uses between 1999 and 2005.
Effective January 1, 2012, Azar became President of Lilly USA, LLC, the largest division of Eli Lilly and Company, and was responsible for the company's entire operations in the United States. Prices for drugs rose substantially under Azar's leadership, including the tripling of the cost of the company's top-selling insulin drug. Also under Azar's watch, Eli Lilly was one of three companies accused in a class-action lawsuit of exploiting the drug pricing system to increase profits for insulin. Eli Lilly was also fined in Mexico for colluding on the price of insulin. In connection with the position, Azar served on the board of directors of the Biotechnology Innovation Organization, a pharmaceutical lobby.
In January 2017, Azar resigned from Eli Lilly "to pursue other career opportunities" as a result of a company reorganization. He also resigned from the board of directors of the Biotechnology Innovation Organization. In his last year at the corporation he earned $2 million.
Secretary of Health and Human ServicesEdit
Nomination and tenureEdit
Many health care advocates raised concerns about the nomination, citing Azar's track record of raising drug prices and his opposition to Obamacare. Critics noted that Azar approved a tripling of the price of insulin while CEO of Eli Lilly. Speaking in favor of his nomination were two former U.S. Senate Majority Leaders, Democrat Tom Daschle and Republican Bill Frist. Both those endorsers were affiliated with the Bipartisan Policy Center, a Washington D.C. think-tank which receives support from Eli Lilly.
In spite of objections, his nomination was relatively smooth. Azar was confirmed on January 24, 2018, with a vote of 55–43, with most Democrats opposed. Voting against him, Oregon Senator Ron Wyden, ranking member on the Senate Finance Committee, said that while Azar was at Eli Lilly, he "never, not one time, signed off on a decrease in the price of a drug." Senator Bernie Sanders said in a press release, "The nomination of Alex Azar, the former head of Eli Lilly's U.S. operations, shows that Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'." "The last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services." During that tenure, Eli was fined for colluding to maintain high drug costs in Mexico.
Azar had additionally consulted with numerous other biopharmaceutical and health insurance corporations regarding government policy, product access, sales and marketing, pricing, reimbursement and distribution. He was confirmed by the Senate on January 24, 2018, and sworn in by Vice President Pence on January 29, 2018.
Affordable Care ActEdit
Azar has been a critic of the Patient Protection and Affordable Care Act (Obamacare) and predicted in 2017, "There will be a piece of legislation passes this year that is called the repeal of Obamacare. I don't know what's going to be in the substance of it, but there will be a piece of legislation that says that." Also regarding the ACA, Azar said the Department of Health and Human Services has latitude to "make it work a little better".
Azar opposes abortion. In a written response to Senator Patty Murray regarding future HHS policy, he said, "The mission of HHS is to enhance the health and well-being of all Americans, and this includes the unborn."
According to The New York Times, Azar differed with his predecessor, Tom Price, in his approach to regulations. Writing in May 2018, The Times said, "in a sharp break from his predecessor — and from most Trump cabinet secretaries — he seems to be relishing the chance to write new regulations, rather than just crossing out Obama-era ones."
Azar learned about the coronavirus threat on January 3, 2020. Azar informed associates that he had alerted Trump on January 18, 2020, regarding the potential danger from COVID-19, but that the president thought he was being "alarmist" as Azar struggled to get Trump's attention to focus on the issue. Despite Azar's warnings, four days later, Trump announced, "We have it totally under control. It’s one person coming in from China." On January 28, 2020, Azar stated that the Trump administration had no plan to declare a public health emergency as the COVID-19 virus spread in China. He asserted that the risk to Americans was minimal, but admitted that authorities in 30 states were monitoring potential cases and added that he would not "hesitate at all to invoke any authorities I need to, to ensure we’re taking all steps to protect the American people, but I’ll do it when it’s appropriate." U.S. Senator Rick Scott and U.S. Representative Vern Buchanan, as well as other Republicans, demanded the declaration of a public health emergency as a means of budgeting necessary federal funding to deal with the potential pandemic. At the time, Azar said, there were just five confirmed cases in the U.S., there was no known person-to-person transmission, and every confirmed U.S. victim had traveled to Wuhan, China (the outbreak's place of origin). "This is potentially a very serious public health threat, but at this time Americans should not worry about their own safety," Azar said. At that point, the disease had killed at least 106 people in China, with more than 4,500 cases confirmed. On January 29, 2020, Azar told Trump that the COVID-19 epidemic was under control.
On February 27, U.S. Representative Jimmy Gomez of California revealed that he had been contacted by a whistleblower from the Department of Health and Human Services (HHS) who had been dispatched to deal with the arrivals of travelers exposed to the coronavirus. There were allegations made that those sent from the HHS to California quarantine sites lacked both sufficient protective clothing and the training necessary to prepare them to deal with the contagion, though they were working alongside CDC personnel who had adequate protective gear. The whistleblower also said that professionals raising concerns about the unsafe practices were subjected to retaliation. Azar responded to the issues raised by Gomez by saying, "Urgency does not compensate for violating isolation and quarantine protocols" and adding, "I'd want to know the full facts and would take appropriate remedial measures." Azar insisted that careful protocols were being observed by all CDC employees.
On February 28, 2020, United States Senate Finance Committee ranking member Ron Wyden wrote Azar to ask why employees of the HHS Administration for Children and Families were involuntarily dispatched to California to meet with quarantined travelers despite lacking expertise in the field and lacking proper information, equipment and training. Wyden also asked why said employees were not cleared to ensure that they had not become carriers of the disease before they were returned to their home stations.
On April 25, 2020, multiple media outlets reported that the White House was weighing a plan to oust Azar due to frustrations over his response to the COVID-19 pandemic. The following day, President Trump tweeted that such reports were "Fake News" and that he has no plans to replace Azar.
Azar picked Brian Harrison, a 37-year old former labradoodle breeder who had no formal education in public health or related fields, but who had worked in the HHS for six years, as HHS's main coordinator for the government's response to the coronavirus.
Centers for Disease Control and PreventionEdit
As Secretary of Health and Human Services, Azar is responsible for the Centers for Disease Control and Prevention (CDC), a key institution in charge of containing contagious diseases. On January 28, 2020, Azar requested that the Chinese government allow a CDC expert team into their country to help them learn more about the virus. Referring to the SARS epidemic 17 years earlier, Azar said, "I can say that the posture of the Chinese government levels of cooperation and interaction with us is completely different from what we experienced in 2003 and I want to commend them for such assistance". The World Health Organization had already agreed to supply international experts to visit China "as soon as possible." Seventy-three possible cases were being monitored in the U.S. Simultaneously, the CDC had ramped up coronavirus screenings of travelers coming into the U.S. at 20 airports. Azar said it might be possible to ban any travelers arriving from China, and all options had to be considered. "Diseases are not terribly good at respecting borders," he added.
Congressional testimony and requests for fundingEdit
On February 25, 2020, Azar appeared before the Senate Appropriations Committee to testify on the danger of and responses to the COVID-19 pandemic. Louisiana Republican Senator John Kennedy asked both Azar and Chad Wolf about the fatality rate in victims. Azar said that the fatality rate of seasonal influenza was about 0.1%, and that the fatality rate of COVID-19 was estimated at between 1% and 2%; however, Azar added that the latter figure was uncertain because there might be many mild coronavirus cases yet unreported. Chad Wolf said that the fatality rate for COVID-19 was between 1.5% and 2%, and said incorrectly that the fatality rate for influenza over the last 10 years in America was similar (about 2%). Kennedy was unhappy with the briefing, saying afterwards, "I thought a lot of the briefing was bullshit... They would answer the question but dodge, bob and weave. I understand there’s a lot they don’t know. I get that. But they need to answer the questions straight up. They all talk about a task force, a committee — a committee's not going to solve this problem."
Trump's officials tried to allay concerns that their request for $2.5 billion was insufficient to address the epidemic. Some Republicans joined Democrats in criticizing the funds requested and found transparency lacking with regard to a coherent strategy to contain the virus. Another Republican, Senate Appropriations Committee Chairman Richard Shelby of Alabama, told Azar: "If you lowball something like this, you'll pay for it later." Pennsylvania Democratic Congressman Brendan Boyle asked Azar how he could defend "draconian cuts" in the CDC budget “at the same time we are facing a unique worldwide health crisis". Two years earlier, a coalition of global health organizations opposed Trump's plans to reduce the CDC's operations in 39 of 49 countries in which it had been helping to rapidly identify and suppress outbreaks of diseases. The coalition wrote to Azar, contending, "These programs are essential to our national defense". In 2018, National Security Adviser John Bolton dismantled the task force charged with responsibility for planning and response to epidemics. The team's leader, Rear Admiral Timothy Ziemer, was the leader of the anti-malarial efforts under presidents Barack Obama and George W. Bush. White House Homeland Security adviser Tom Bossert, who had advocated a comprehensive biodefense strategy against both pandemics and potential biological attacks, departed from the White House on the same day Bolton arrived.
HHS purchase of 500,000 doses of RemdesivirEdit
On June 29, 2020, it was announced that the U.S. Department of Health and Human Services (HHS) had agreed to buy 500,000 remdesivir treatment courses. The announcement mentioned that each five-day course of remdesivir (for treatment of a patient with coronavirus) would cost at least US$2,340.00. HHS Secretary Alex Azar was quoted, and had said (in a press release) that "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it".
On March 2, 2020, Azar was criticized for unpreparedness that may have accelerated the spread of the virus. Some critics focused on the lack of definitive testing of those who might be spreading the virus. China had tested over 1,000,000 people, while the CDC had tested less than 500 and its results had been undermined by problems with accuracy and potential contamination. There was substantial internal feuding with regard to formulation of policy at HHS and the CDC.
Azar argued that the pharmaceutical industry was best poised to discover, manufacture, and market a vaccine for coronavirus. When asked about the cost of vaccines, Azar responded that the price might be high, but that an important vaccine would be created even if many Americans could not afford it.
In September 2020, Azar forbade health agencies including the Food and Drug Administration from making new rules on foods, medicines, medical devices or other products, including vaccines, without his permission. His memo to the agencies declared that such power “is reserved to the Secretary.” Health advocates said that the memo raised questions about political meddling and might slow down decision-making. It was unclear if the change would affect work on COVID-19 vaccines.
On August 9, 2020, a delegation led by Alex Azar on a U.S. Air Force C-40B Administrative Plane arrived in Taiwan Taipei Songshan Airport; he was the first member of the U.S. Cabinet to visit Taiwan in six years. Azar said the trip was to convey Trump's support for Taiwan's leadership in global health, reiterate U.S. support for Taiwan, and cooperate on global health and health safety issues. On the afternoon of the 10th, under the witness of Chen Shih-chung and Azar, the chairman of Taiwan Council for U.S. Affairs Yang Jen-ni and American Institute in Taiwan Taipei Office Director Brent Christensen, on behalf of both parties, signed a Memorandum of Understanding on Medical and Health Cooperation in Taipei.
Azar is an Antiochian Orthodox Christian and formerly Episcopalian. He is of Lebanese, Ukrainian, English and Swiss descent. Before his nomination, he lived in Indianapolis with his wife and two children. Azar served for two years on the board of HMS Holdings. He is currently on the board of the American Council on Germany, where he is Chairman of the Strategic Planning Committee, and the Indianapolis Symphony Orchestra.
He has previously served on the board of directors of the Healthcare Leadership Council, where he was Treasurer; the National Association of Manufacturers; and the Indianapolis International Airport Authority, where he was Chairman of the Human Resources Committee.
In 2020, Azar revealed he has celiac disease while discussing a U.S. Food and Drug Administration rule related to gluten-free labeling for fermented foods.
- "Jennifer Azar former Deputy Secretary Alex Azar's Wife". Daily Entertainment News. Retrieved April 30, 2020.
- Dixon, Kim (November 20, 2017). "HHS nominee Azar made millions working for drugmaker Lilly". Retrieved January 24, 2018.
- "'Only in America': Trump nominates Salisbury's Azar for top Cabinet post". Retrieved February 3, 2018.
- "Obituary of ZARISKY, Sarah L. (Lamb), Cambria County, PA". camgenpa.com. Archived from the original on January 31, 2018. Retrieved February 3, 2018.
- Groppe, Maureen (November 13, 2017). "Who is Alex Azar? Former drugmaker CEO and HHS official nominated to head agency". USA Today. Retrieved January 25, 2018.
- "Biography of Alex Michael Azar II, Deputy Secretary". United States Department of Health & Human Services. June 19, 2006. Archived from the original on February 6, 2007. Retrieved December 31, 2018.
- Aviv, Diana (October 21, 2005). "Faculty Biographies - 3rd Annual Washington Healthcare Summit" (PDF). American Bar Association. Archived from the original (PDF) on December 31, 2018. Retrieved December 31, 2018.
- Mystal, Elie. "Could HHS Secretary Alex Azar Derail Brett Kavanaugh?". Above The Law. Retrieved September 25, 2018.
- Newman, Katelyn (January 29, 2018). "10 Things You Didn't Know About Alex Azar". U.S. News & World Report. Retrieved March 15, 2020.
- Risen, James (September 13, 1994). "Starr Names His First Whitewater Aides: Investigation: Independent counsel announces appointments to fill out prosecution team. He names a Fiske holdover as a top deputy". Los Angeles Times. Retrieved January 25, 2018.
- Schmidt, Susan (September 13, 1994). "Whitewater Counsel Assembles Team". The Washington Post. Retrieved January 25, 2018.
- "Alex M. Azar II - Biography". World Congress.
- "PN492 - Nomination of Alex Azar II for Department of Health and Human Services, 107th Congress (2001-2002)". United States Congress. August 3, 2001.
- "Presidential Nomination: Alex Michael Azar". November 2, 2002. Archived from the original on November 2, 2002. Retrieved July 7, 2018.
- "PN430 - Nomination of Alex Azar II for Department of Health and Human Services, 109th Congress (2005-2006)". United States Congress. July 22, 2005.
- "Presidential Nomination: Alex Michael Azar". November 22, 2006. Archived from the original on November 22, 2006. Retrieved February 3, 2018.
- "Azar resigns as HHS deputy secretary". BioCentury. January 17, 2007.(subscription required)
- Mathis-Lilley, Ben (November 13, 2017). "Trump Health Secretary Nominee Left Job Overseeing Eli Lilly Investigation to Become Eli Lilly's Top Lobbyist". Slate.
- "Lilly Announces Changes in Senior Management" (Press release). PRNewswire. October 11, 2011.
- Karlin-Smith, Sarah. "Trump's HHS secretary nominee boosted drug prices while at Eli Lilly". POLITICO.
- Nisen, Max (November 13, 2017). "Alex Azar Is a Friend to Health-Care Companies". Bloomberg L.P.
- Vazquez, Maegan (November 13, 2017). "Trump picks former pharma exec, ex-Bush official to lead HHS department". CNN.
- "Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities" (Press release). PRNewswire. January 5, 2017.
- CRONYISM AND CONFLICTS OF INTEREST IN TRUMP’S CORONAVIRUS TASK FORCE, The Intercept, Sharon Lerner, February 29, 2020. Retrieved March 12, 2020.
- Mangan, Dan (November 13, 2017). "Trump nominates former drug company executive Alex Azar as next Health and Human Services secretary". CNBC.
- Advocacy Groups Slam Azar Ahead of Committee Hearing, HEALTHCAREDIVE, David Lim, January 4, 2018. Retrieved February 28, 2020.
- What You Need to Know about Alex Azar, Trump's HHS Nominee, Scientific American, Dina Fine Maron, November 28, 2017. Retrieved March 10, 2020.
- HHS Secretary Alex Azar now wants the Trump administration to import cheaper drugs from Canada, Newsweek, Alexandra Hutzler, July 31, 2019. Retrieved February 28, 2020.
- PUNDITS FUNDED BY DRUG COMPANY APPLAUD ITS TAKEOVER OF TRUMP HEALTH DEPARTMENT, The Intercept, Zaid Jilani, November 29, 2017. Retrieved March 12, 2020.
- "Senate Confirms Trump Nominee Alex Azar as Health Secretary". January 24, 2018. Retrieved January 24, 2018.
- Meet HHS Secretary Alex Azar, the Official Chairing the Coronavirus Task Force, Time Magazine, Tessa Berenson, February 27, 2020. Retrieved February 28, 2020.
- Mangan, Dan (January 29, 2018). "Alex Azar sworn in as Trump's new health-care chief". cnbc.com. Retrieved March 29, 2019.
- "Federal Commission on School Safety". United States Department of Education. Retrieved April 25, 2020.
- "There's a New Health Secretary. What Will He Mean for Women's Health?". Time. Retrieved January 25, 2018.
- "Trump's New Health and Human Services Secretary Is a Joyful Regulator". The New York Times. May 18, 2018. Retrieved May 19, 2018.
- "Health Chief's Early Missteps Set Back Coronavirus Response". The Wall Street Journal. April 22, 2020.
- The Worst President. Ever., The Washington Post, Max Boot, April 5, 2020. Retrieved April 6, 2020.
- "Trump says he trusts China's Xi on coronavirus and the US has it 'totally under control'". CNBC. January 22, 2020.
- What the best public health minds know — and don’t know — about Wuhan coronavirus, Politico, Joanne Kenen, January 28, 2020. Retrieved February 28, 2020.
- Whistleblower Feds helping evacuees lacked virus protection, The Washington Post, Ricardo Alonso-Zaldivar (AP), February 27, 2020. Retrieved February 28, 2020.
- Coronavirus updates: WHO increases risk to 'very high,' tells governments to 'wake up', USA Today, Adrianna Rodriguez, February 28, 2020. Retrieved February 28, 2020.
- Sen. Ron Wyden asks HHS how agency employees are tested for coronavirus, Axios, Orion Rummler, February 28, 2020. Retrieved February 29, 2020.
- "Special Report: Former Labradoodle breeder was tapped to lead U.S. pandemic task force". Reuters. April 24, 2020. Retrieved May 16, 2020.
- HHS chief: No plans to declare public health emergency over coronavirus, The Hill, Nathaniel Weixel, January 28, 2020. Retrieved February 27, 2020.
- "02 25 20 Kennedy questions Secretary Azar on coronavirus during Appropriations Committee hearing; 3:24".
- "02 25 20 Kennedy questions Acting Sec. Wolf on coronavirus during Appropriations Committee hearing; 2:21".
- "Trump's DHS head has a brutal exchange on coronavirus — courtesy of a GOP senator". The Washington Post. February 25, 2020. Retrieved March 2, 2020.
- "Coronavirus's spread in U.S. is 'inevitable,' CDC warns". Washington Post.
- Coronavirus triggers swift bipartisan backlash against Trump, Politico, Rachel Roubein and Alice Miranda Ollstein, February 25, 2020. Retrieved February 26, 2020.
- Coronavirus's spread in U.S. is 'inevitable,' CDC warns, The Washington Post, Erica Werner, Yasmeen Abutaleb, Lena H. Sun and Lenny Bernstein, February 25, 2020. Retrieved February 26, 2020.
- Trump says he can bring in coronavirus experts quickly. The experts say it's not that simple, The Washington Post, Beth Reinhard, Emma Brown and Neena Satija February 27, 2020. Retrieved February 29, 2020.
- White House sidelines Azar from coronavirus response, Politico, Dan Diamond, Sarah Owermohle, and Meridith Mcgraw, March 5, 2020. Retrieved March 11, 2020.
- Keane, Sean (June 29, 2020). "US to buy 500,000 remdesivir coronavirus treatment courses at $2,340 each". cnet (cnet.com). CBS Interactive (ViacomCBS). Archived from the original on June 29, 2020.
The US Department of Health and Human Services has agreed to buy 500,000 remdesivir treatment courses, in the wake of clinical trials revealing the drug can help patients recover more quickly from the coronavirus. A five-day course will cost $2,340, or $3,120 for commercially insured patients, biotech firm Gilead Sciences said.
Early last month, the Food and Drug Administration issued an emergency authorization for remdesivir to be used in cases of COVID-19 when patients were "hospitalized with severe disease," shortly after the drug showed "clear-cut positive effect" in a US trial. [...]
"To the extent possible, we want to ensure that any American patient who needs remdesivir can get it," HHS Secretary Alex Azar said in a release.
- Azar in the crosshairs for delays in virus tests, Politico, DAN DIAMOND and ADAM CANCRYN, March 2, 2020. Retrieved March 2, 2020.
- Relman, Eliza (February 26, 2020). "The Trump administration reversed course after saying the coronavirus vaccine might not be affordable for all Americans". Business Insider. Retrieved April 3, 2020.
- Kaplan, Sheila (September 19, 2020). "In 'Power Grab,' Health Secretary Azar Asserts Authority Over F.D.A." The New York Times. ISSN 0362-4331. Retrieved September 20, 2020.
- 陳韻聿 (August 6, 2020). "美衛生部長率團抵台 行政專機星條旗象徵高規格" (in Chinese). 中央社. Archived from the original on August 9, 2020. Retrieved August 25, 2020.
- AIT - Taipei Main Office (August 5, 2020). "HHS Secretary Alex Azar to Lead Delegation to Taiwan in First Visit by a U.S. HHS Secretary". American Institute in Taiwan. Retrieved August 5, 2020.
- Chen Yunyu (August 10, 2020). "China is dissatisfied with visiting Taiwan Isa wants Beijing to ignore Taiwan affairs" (in Chinese). Central News Agency. Retrieved August 10, 2020.
- 國際合作組 (August 10, 2020). "首次我與美國衛生部簽署「醫衛合作瞭解備忘錄」" (Press release) (in Chinese). 衛生福利部. Retrieved August 10, 2020.
- Chen Shih-chung、Alex Azar (August 10, 2020). AIT-TECRO衛生合作備忘錄簽署儀式 (YouTube) (in Chinese). 台北: 公視新聞網.
- "Senate Hearing 115-438". Congress.gov. Library of Congress. January 9, 2018. Retrieved April 23, 2020.
Religious memberships: Saints Peter and Paul Antiochian Orthodox Church....Saint John's Episcopal Church....Episcopal Church at Yale
- "Obituary of Dr. Alex Azar". Holloway Funeral Home. April 6, 2020. Retrieved April 23, 2020.
When he moved to Salisbury, he joined St. Peter’s Episcopal.[permanent dead link]
- Delkic, Melina (November 13, 2017). "Who is Alex Azar? Trump's New HHS Secretary Pick Lobbied for Big Pharma". Newsweek.
- Braun, Stephen (November 20, 2017). "Health secretary nominee reaped big earnings from drug industry tenure". Stat News. Associated Press. Retrieved January 24, 2018.
Harriet S. Rabb
| General Counsel of the United States Department of Health and Human Services
| United States Deputy Secretary of Health and Human Services
| United States Secretary of Health and Human Services
|U.S. order of precedence (ceremonial)|
as Secretary of Labor
| Order of Precedence of the United States
as Secretary of Health and Human Services
as Secretary of Housing and Urban Development
|U.S. presidential line of succession|
as Secretary of Labor
| 12th in line
as Secretary of Health and Human Services
as Secretary of Housing and Urban Development